STOCK TITAN

Haemonetics Corporation (HAE) DEF 14A Filings

HAE NYSE

Here are the DEF 14A proxy statements from Haemonetics Corporation (HAE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HAE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAE filings page.

Rhea-AI Summary

Haemonetics Corporation is asking shareholders to elect eight directors, approve advisory say‑on‑pay, ratify Ernst & Young as auditor, and update its long‑term incentive and employee stock purchase plans at the 2026 Annual Meeting on July 24 in Boston.

The proxy highlights strong fiscal 2026 results: revenue of $1.334 billion, adjusted EPS of $4.96, free cash flow of $209.9 million and adjusted operating margin of 25.4%, including 9.5% organic ex‑CSL revenue growth and a 45.2% free cash flow increase. It notes robust shareholder support, with approximately 98.6% approval of 2026 executive pay, and explains a pay‑for‑performance program using cash bonuses tied to revenue, EPS and free cash flow plus PSU, RSU and option awards. The filing also details an independent, skills‑diverse board, a waiver of the age‑75 guideline to retain Board Chair Ellen Zane, strong governance practices such as majority voting and the right to call special meetings, and extensive shareholder outreach covering about 36% of shares.